Introduction
Driven primarily by continued uptake of Shire’s market leading ADHD drug, Adderall XR (amphetamine extended release), seven major market ADHD revenues grew strongly at a compound annual growth rate (200408) of 13.5% to reach almost $4.4 billion in 2008. Ongoing uptake of Shire’s Vyvanse (lisdexamfetamine), was also a key contributor to market growth between 2007 and 2008.
Reasons to Purchase
*This report gives a strategic analysis of the likely impact that recent events will have on the future ADHD market.
*Includes sales forecasts for the key ADHD brands and generics as well as pipeline agents in the seven major markets to 2018.
*Quantify the current and future size of the seven major ADHD markets.
Other selected research from the 'Markets' category:
Biotech Financing in the Credit Crisis: Strategies for a radically altered landscape
An overview of licensing trends in the US during 2006-08, and current/future biotech financing strategies in today’s changing economic climate. Learn More
Obesity Market Forecast
The obesity market is easily characterized as attractive, featuring a booming patient potential needing long term therapy, but repeated product withdrawals and failed pipeline candidates highlight the reality of increasingly cautious regulatory bodies, reluctant payers, and a clinical community that puts more stock in diet and exercise. Learn More
Other selected research from the 'Neurological disorders' category:
Stakeholder Insight: Cognitive Impairment in Schizoaffective Disorder - Inevitable or Treatable?
Cognitive impairment is regarded as a core deficit of schizophrenia; the primary unmet need is the availability of an effective drug for the treatment of cognitive impairment in schizophrenia (CIS). However manufacturers will need to carefully consider how to develop and market such a drug, and increase awareness of the disorder in patients, carers and prescribers. Learn More
Pipeline Insight: Schizophrenia - Asenapine; a future market leader?
The global schizophrenia market will continue to grow until 2010, when revenues will reach $3.8 billion. However, despite the launch of numerous pipeline schizophrenia drugs, the market will begin to decline thereafter owing to the US launch of generic risperidone in 2007, followed by generic versions of olanzapine, quetiapine and ziprasidone from 2011 onwards. Learn More